OSE Immunotherapeutics SA (EPA:OSE)

France flag France · Delayed Price · Currency is EUR
6.45
+0.04 (0.62%)
Aug 14, 2025, 11:33 AM CET
-8.38%
Market Cap 146.58M
Revenue (ttm) 83.44M
Net Income (ttm) 37.45M
Shares Out 22.87M
EPS (ttm) 1.46
PE Ratio 4.39
Forward PE 7.08
Dividend n/a
Ex-Dividend Date n/a
Volume 40,139
Average Volume 133,568
Open 6.42
Previous Close 6.41
Day's Range 6.30 - 6.53
52-Week Range 4.42 - 11.58
Beta 0.51
RSI 64.61
Earnings Date Sep 26, 2025

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 64
Stock Exchange Euronext Paris
Ticker Symbol OSE
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.